{"id":528755,"date":"2021-08-17T07:08:10","date_gmt":"2021-08-17T11:08:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/"},"modified":"2021-08-17T07:08:10","modified_gmt":"2021-08-17T11:08:10","slug":"helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/","title":{"rendered":"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke"},"content":{"rendered":"
\n

NEWTOWN, Pa., Aug. 17, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation from the U.S. Food and Drug Administration (\u201cFDA\u201d) for its PoNS\u2122 device with the proposed indication for use as a temporary treatment of dynamic gait and balance deficits due to symptoms from stroke, to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over.<\/p>\n

\u201cWe are very pleased to announce the receipt of Breakthrough Designation for our PoNS device to treat stroke-induced gait and balance deficits,\u201d said Helius CEO, Dane Andreeff. \u201cStrokes are a large and growing cause of long-term disability in the United States. An estimated 7 million Americans are living with stroke-related complications, and more than 80% of stroke survivors are estimated to develop gait impairment.1<\/sup>\u201d<\/p>\n

Mr. Andreeff continued: \u201cObtaining Breakthrough Designation represents an important milestone in our path to providing this underserved patient population with a non-drug, non-implantable treatment option that has the potential to significantly improve their gait and balance, their ability to walk and perform daily tasks. We look forward to building on this achievement by utilizing the Breakthrough Devices Program to facilitate our pursuit of U.S. regulatory clearance for treatment of stroke-induced symptoms in close collaboration with the FDA.\u201d<\/p>\n

The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.<\/p>\n

The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the FDA\u2019s mission to protect and promote public health.<\/p>\n

The Breakthrough Devices Program offers manufacturers such as Helius an opportunity to interact with the FDA\u2019s experts through several different program options to efficiently address topics as they arise during the premarket review phase, which can help manufacturers receive feedback from the FDA and identify areas of agreement in a timely way. Manufacturers can also expect prioritized review of their submission.<\/p>\n

\n About Helius Medical Technologies, Inc.<\/strong>\n <\/p>\n

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company\u2019s purpose is to develop, license and acquire unique and non-invasive platform including the Portable Neuromodulation Stimulator (PoNS\u2122). For more information, visit www.heliusmedical.com<\/a>.<\/p>\n

\n About the PoNS\u2122 Device and PoNS Treatment\u2122<\/strong>\n <\/p>\n

The Portable Neuromodulation Stimulator (PoNS\u2122) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (\u201cMS\u201d) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (\u201cmmTBI\u201d) and is to be used in conjunction with physical therapy. The PoNS\u2122\u00a0is an investigational medical device in Australia (\u201cAUS\u201d) and is currently under premarket review by the AUS Therapeutic Goods Administration.<\/p>\n

\n Investor Relations Contact:<\/strong>\n <\/p>\n

Westwicke on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com<\/a><\/p>\n

\n Cautionary Disclaimer Statement:\u00a0<\/strong>\n <\/p>\n

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as \u201cbelieve,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201cgoal,\u201d \u201caim to,\u201d \u201clook forward\u201d and similar expressions. Such forward-looking statements include, among others, statements regarding the Company\u2019s regulatory plans and pursuit of U.S. regulatory clearance for treatment of stroke-related symptoms.<\/p>\n

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include: uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process, other development activities, the Company\u2019s capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, the Company\u2019s ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company\u2019s ability to secure contracts with rehabilitation clinics, the Company\u2019s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company\u2019s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, manufacturing and supply chain risks, potential changes to the MCIT program resulting from the 60-day deferral of the program implementation, ongoing government regulation, and other risks detailed from time to time in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2020, its Quarterly Report on Form 10-Q for the quarter ended June\u00a030, 2021 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.<\/p>\n

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.<\/p>\n

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.<\/p>\n

\n 1<\/sup> Carmen M. Cirstea. Gait Rehabilitation After Stroke, Should we re-evaluate our practice? Stroke 2020;51(10):2892-94.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEWTOWN, Pa., Aug. 17, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation from the U.S. Food and Drug Administration (\u201cFDA\u201d) for its PoNS\u2122 device with the proposed indication for use as a temporary treatment of dynamic gait and balance deficits due to symptoms from stroke, to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over. \u201cWe are very pleased to announce the receipt of Breakthrough Designation for our PoNS device to treat stroke-induced gait and balance deficits,\u201d said Helius CEO, Dane Andreeff. \u201cStrokes are a large and growing cause … <\/p>\n

Continue reading “Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-528755","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHelius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWTOWN, Pa., Aug. 17, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation from the U.S. Food and Drug Administration (\u201cFDA\u201d) for its PoNS\u2122 device with the proposed indication for use as a temporary treatment of dynamic gait and balance deficits due to symptoms from stroke, to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over. \u201cWe are very pleased to announce the receipt of Breakthrough Designation for our PoNS device to treat stroke-induced gait and balance deficits,\u201d said Helius CEO, Dane Andreeff. \u201cStrokes are a large and growing cause … Continue reading "Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-17T11:08:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke\",\"datePublished\":\"2021-08-17T11:08:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/\"},\"wordCount\":1098,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/\",\"name\":\"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=\",\"datePublished\":\"2021-08-17T11:08:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/","og_locale":"en_US","og_type":"article","og_title":"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke - Market Newsdesk","og_description":"NEWTOWN, Pa., Aug. 17, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation from the U.S. Food and Drug Administration (\u201cFDA\u201d) for its PoNS\u2122 device with the proposed indication for use as a temporary treatment of dynamic gait and balance deficits due to symptoms from stroke, to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over. \u201cWe are very pleased to announce the receipt of Breakthrough Designation for our PoNS device to treat stroke-induced gait and balance deficits,\u201d said Helius CEO, Dane Andreeff. \u201cStrokes are a large and growing cause … Continue reading \"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-17T11:08:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke","datePublished":"2021-08-17T11:08:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/"},"wordCount":1098,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/","name":"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=","datePublished":"2021-08-17T11:08:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMDMyOCM0MzYxODc2IzIwODIwMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/528755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=528755"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/528755\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=528755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=528755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=528755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}